Welcome to our dedicated page for NorthView Acquisition news (Ticker: PFSA), a resource for investors and traders seeking the latest updates and insights on NorthView Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NorthView Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NorthView Acquisition's position in the market.
Profusa (NASDAQ:PFSA), a commercial stage digital health company, has completed its business combination with NorthView Acquisition Corp (NVAC). The company's common stock will begin trading on Nasdaq under the ticker "PFSA" on July 14, 2025.
The combined company secured $9 million through a secured convertible promissory note from an institutional investor, with potential access to up to $20 million under the convertible note facility. The funds will support transaction costs and working capital needs.
Profusa specializes in tissue-integrating biosensors that can monitor body chemistry continuously, transmitting data to smartphone applications and utilizing AI technologies for health management, particularly focusing on conditions like diabetes, critical limb ischemia, and peripheral arterial disease.
FAQ
What is the current stock price of NorthView Acquisition (PFSA)?
